BJ O'Connor, LJ Towse and PJ Barnes
Clinical Studies Unit, Royal Brompton National Heart and Lung Hospital, London, United Kingdom.

Inhaled anticholinergic drugs are effective in the treatment of chronic obstructive pulmonary diseases (COPD), of acute asthma, and of some patients with nocturnal asthma. Tiotropium bromide (tiotropium) is a novel anticholinergic agent with a long duration of action and kinetic selectivity for M1- and M3-subtypes of muscarinic receptors. We investigated the duration of protection of a single dose of inhaled tiotropium against methacholine-induced bronchoconstriction in 12 male atopic asthmatic volunteers in a double-blind, placebo-controlled study. On four separate occasions 8 to 24 d apart, methacholine PC20 was measured serially for up to 48 h after placebo and after three doses of tiotropium (10, 40, and 80 microg). Each dose of tiotropium produced mild bronchodilatation as measured by an increase in FEV1 of between 5.5 and 11.1% from baseline, that was sustained for 24 h. There was significant dose-dependent protection against methacholine challenge at 2 h of 5.0 +/- 1.1, 7.1 +/- 0.5, and 7.9 +/- 0.7 (mean +/- SEM) doubling doses after 10, 40, and 80 microg respectively, and this persisted for 48 h. There were no adverse effects reported at any dose. The prolonged bronchodilator response and protection against methacholine challenge suggest that tiotropium may be useful in the treatment of COPD and nocturnal asthma and that once-daily dosing may be sufficient.

This article has been cited by other articles:

				H. Iwamoto, A. Yokoyama, N. Shiota, H. Shoda, Y. Haruta, N. Hattori, and N. Kohno Tiotropium bromide is effective for severe asthma with noneosinophilic phenotype Eur. Respir. J., June 1, 2008; 31(6): 1379 - 1380. [Full Text] [PDF]

				R C Reddy Severe asthma: approach and management Postgrad. Med. J., March 1, 2008; 84(989): 115 - 120. [Abstract] [Full Text] [PDF]

				N. A. Hanania and J. F. Donohue Pharmacologic Interventions in Chronic Obstructive Pulmonary Disease: Bronchodilators Proceedings of the ATS, October 1, 2007; 4(7): 526 - 534. [Abstract] [Full Text] [PDF]

				R G Barr, J Bourbeau, C A Camargo, and F S F Ram Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis Thorax, October 1, 2006; 61(10): 854 - 862. [Abstract] [Full Text] [PDF]

				S. R. Salpeter, N. S. Buckley, T. M. Ormiston, and E. E. Salpeter Meta-Analysis: Effect of Long-Acting {beta}-Agonists on Severe Asthma Exacerbations and Asthma-Related Deaths Ann Intern Med, June 20, 2006; 144(12): 904 - 912. [Abstract] [Full Text] [PDF]

				T. T. Hansel, H. Neighbour, E. M. Erin, A. J. Tan, R. C. Tennant, J. G. Maus, and P. J. Barnes Glycopyrrolate Causes Prolonged Bronchoprotection and Bronchodilatation in Patients With Asthma Chest, October 1, 2005; 128(4): 1974 - 1979. [Abstract] [Full Text] [PDF]

				H. Somand and T. L Remington Tiotropium: A Bronchodilator for Chronic Obstructive Pulmonary Disease Ann. Pharmacother., September 1, 2005; 39(9): 1467 - 1475. [Abstract] [Full Text] [PDF]

				N. J. Gross Tiotropium Bromide Chest, December 1, 2004; 126(6): 1946 - 1953. [Abstract] [Full Text] [PDF]

				P M A Calverley, A Lee, L Towse, J van Noord, T J Witek, and S Kelsen Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease Thorax, October 1, 2003; 58(10): 855 - 860. [Abstract] [Full Text] [PDF]

				M. T. Borchers, T. Biechele, J. P. Justice, T. Ansay, S. Cormier, V. Mancino, T. M. Wilkie, M. I. Simon, N. A. Lee, and J. J. Lee Methacholine-induced airway hyperresponsiveness is dependent on G{alpha}q signaling Am J Physiol Lung Cell Mol Physiol, July 1, 2003; 285(1): L114 - L120. [Abstract] [Full Text] [PDF]

				J.A. van Noord, J.J. Smeets, F.L.J. Custers, L. Korducki, and P.J.G. Cornelissen Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease Eur. Respir. J., April 1, 2002; 19(4): 639 - 644. [Abstract] [Full Text] [PDF]

				H. P Wiedemann Tiotropium improved lung function more than ipratropium in chronic obstructive pulmonary disease Evid. Based Med., November 1, 2000; 5(6): 169 - 169. [Full Text]

				M. R. LITTNER, J. S. ILOWITE, D. P. TASHKIN, M. FRIEDMAN, C. W. SERBY, S. S. MENJOGE, and T. J. WITEK Jr. Long-Acting Bronchodilation with Once-Daily Dosing of Tiotropium (Spiriva) in Stable Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., April 1, 2000; 161(4): 1136 - 1142. [Abstract] [Full Text]

				J A van Noord, T A Bantje, M E Eland, L Korducki, and P J G Cornelissen A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease Thorax, April 1, 2000; 55(4): 289 - 294. [Abstract] [Full Text]

				P. J. Barnes The Pharmacological Properties of Tiotropium Chest, February 1, 2000; 117(2_suppl): 63S - 66S. [Abstract] [Full Text] [PDF]